Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 +/- Adebrelimab in HR+/HER2-low Breast Cancer
NCT06340230Phase 2Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Aug 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Shengjing Hospital of China Medical University. Started Aug 2024; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06340230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340230.